Evidence map›Paper›PMID 38191097›Full record

ArticleBioorganic & medicinal chemistry letters2024

Expanded library of novel 2,3-pyrrolidinedione analogues exhibit anti-biofilm activity.

Minhua Nie, M Alejandro Valdes-Pena, Bram H Frohock, Emma Smits, Jennifer C Daiker, Jessica M Gilbertie, Lauren V Schnabel, Joshua G Pierce

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Pyrrolidine-2,3-diones: heterocyclic scaffolds that inhibit and eradicateChemical communications (Cambridge, England) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Minhua NieDepartment of Chemistry, College of Sciences, NC State University, Raleigh, NC 27695, USA; Comparative Medicine Institute, NC State University, Raleigh, NC 27695, USA.
M Alejandro Valdes-PenaDepartment of Chemistry, College of Sciences, NC State University, Raleigh, NC 27695, USA; Comparative Medicine Institute, NC State University, Raleigh, NC 27695, USA.
Bram H FrohockDepartment of Chemistry, College of Sciences, NC State University, Raleigh, NC 27695, USA; Comparative Medicine Institute, NC State University, Raleigh, NC 27695, USA.
Emma SmitsDepartment of Chemistry, College of Sciences, NC State University, Raleigh, NC 27695, USA; Comparative Medicine Institute, NC State University, Raleigh, NC 27695, USA.
Jennifer C DaikerDepartment of Chemistry, College of Sciences, NC State University, Raleigh, NC 27695, USA; Department of Clinical Sciences College of Veterinary Medicine, NC State University, 1060 William Moore Drive, Raleigh, NC 27607, USA; Comparative Medicine Institute, NC State University, Raleigh, NC 27695, USA.
Jessica M GilbertieDepartment of Clinical Sciences College of Veterinary Medicine, NC State University, 1060 William Moore Drive, Raleigh, NC 27607, USA; Comparative Medicine Institute, NC State University, Raleigh, NC 27695, USA.
Lauren V SchnabelDepartment of Clinical Sciences College of Veterinary Medicine, NC State University, 1060 William Moore Drive, Raleigh, NC 27607, USA; Comparative Medicine Institute, NC State University, Raleigh, NC 27695, USA.
Joshua G PierceDepartment of Chemistry, College of Sciences, NC State University, Raleigh, NC 27695, USA; Comparative Medicine Institute, NC State University, Raleigh, NC 27695, USA. Electronic address: jgpierce@ncsu.edu.
North Carolina State University · US

Funding

Synthesis and Chemical Biology of Bioactive Natural ProductsR35GM139583 · NIGMS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI PIERCE, JOSHUA G. · 2021 to 2025
$2.5M
NIGMS NIH HHS R35 GM139583
6 · The paper itself

Abstract

Herein we report a new library of 2,3-pyrrolidinedione analogues that expands on our previous report on the antimicrobial studies of this heterocyclic scaffold. The novel 2,3-pyrrolidinediones reported herein have been evaluated against S. aureus and methicillin-resistant S. aureus (MRSA) biofilms, and this work constitutes our first report on the antibiofilm properties of this class of compounds. The antibiofilm activity of these 2,3-pyrrolidinediones has been assessed through minimum biofilm eradication concentration (MBEC) and minimum biofilm inhibition concentration (MBIC) assays. The compounds displayed antibiofilm properties and represent intriguing scaffolds for further optimization and development.

Indexed as

Anti-Bacterial AgentsMethicillin-Resistant Staphylococcus aureusBiofilmsMethicillin ResistanceMicrobial Sensitivity TestsStaphylococcus aureusAnti-Bacterial Agents2, 3-pyrrolidinedioneAntibioticsAntimicrobial resistanceBiofilmsNatural products

Identifiers

PMID38191097
PMCPMC10872213
OpenAlexW4390637621

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.